Summary

Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.



Report Facts

Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. The ongoing research on this therapy will replace the chemotherapeutics treatments in the near future thereby reducing its toxic side effects. Billions of dollars are spent on the chemotherapy treatments annually. Different Biotechnology companies and Pharma Companies are collaborating in all area of ADCs like linker technology, antibody production and conjugation process. Seattle Genetics’s Brentuximab vedotin and Roche’s trastuzumab emtansine are the only ADCs approved which have together made USD 523 millions sales in 2013. There are total 264 ADCs in pipeline with 253 ADCS are developing only for Oncology indications. Pipeline is very rich with four potential drugs in Phase III stage out of which Kadcyla and Adcetris are undergoing clinical studies for different conditions. According to DelveInsight Analysis, North America has the highest number of development in ADCs with 161 ADCs and 65 Active companies followed by Europe with 38 active companies and 81 products and Asia Pacific with 18 ADCs in development.



Scope

• A snapshot of the global Antibody-Drug Conjugate market scenario, market trends & drivers, manacles of Antibody-Drug Conjugate.

• A review of the marketed Antibody-Drug Conjugate products and marketing status

• Coverage of global antibody-drug conjugate therapies under development across the globe covering territories

• Competitive landscape of investigational products for key players and key therapy areas.

• The Antibody-Drug Conjugate report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information

• The Report also provides the pre-clinical and clinical outcomes of the therapies

• The Report has covered the targets and detailed mechanism of action

• Report has highlighted the licensing opportunities and funding details for therapies

• The report also gives the information of dormant and discontinued pipeline projects



Reasons to Buy

• Complete Market and Pipeline intelligence and complete understanding over therapeutics development for Antibody-Drug Conjugate

• Devise corrective measures for pipeline projects by understanding Therapy area specific therapies

• Developing strategic initiatives to support your Antibody-Drug Conjugate development activities.

• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

• Evaluate the marketing and pipeline strategy for antibody-drug conjugate therapies and their funding details.

• Identifying the upcoming leaders in the Antibody-Drug Conjugate market in the coming years.



Browse complete Report on:
http://www.aarkstore.com/pharmaceuticals-healthcare/106496/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape



Table of Content

Introduction 13
Executive Summary 13
Scope of the Report 14
Antibody-Drug Conjugate Introduction 15
Historical Perspective of Antibody-Drug Conjugate 15
Design of Antibody-Drug Conjugate 17
Different components of Antibody-Drug Conjugate 17
Immunocongugate–A distinct class of therapeutics in Oncology 20
Advantages of ADC over Traditional Therapies 21
Important Hurdles Faced in Development and Commercialization of ADC 22
Current scenario of Marketed and Pipeline Antibody-Drug Conjugate 23
Antibody-Drug Conjugate Marketed Scenario 23



Related Reports:

http://www.aarkstore.com/pharmaceuticals-healthcare/106540/her-2-positive-breast-cancer-market-in-the-us-2015-2019

http://www.aarkstore.com/pharmaceuticals-healthcare/106533/global-small-cell-lung-cancer-therapeutics-market-2015-2019

http://www.aarkstore.com/pharmaceuticals-healthcare/106531/global-osteoarthritis-market-2015-2019

http://www.aarkstore.com/pharmaceuticals-healthcare/106524/global-laboratory-information-management-system-lims-market-2015-2019



About Aarkstore Enterprise

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.


Contact Details:

Aarkstore Enterprise
Phone: +91 998 729 5242
Email: [email protected]
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/